_{First a message from our friends at RAD INTEL (sponsor)}

The $0.85 window closes tonight - don't miss it.

Dear Reader,

It's easy to see why 14,000+ investors and global giants are in on the action. Their AI software helps major brands pinpoint their perfect audience and predict what content drives action.

The proof is recurring seven-figure contracts with Fortune 1000 brands.

Think Google/Facebook-style targeting, but smarter, faster, and built for the next era of AI. Major brands across entertainment, healthcare, and gaming are already using RAD Intel, and the company has backing from multiple Fidelity funds and insiders from Meta, Google, and Amazon.

Here's the kicker: RAD Intel is still private – but you can still get $0.85 shares through tonight. Plus, 15% bonus shares are still available.

They've already reserved their Nasdaq ticker – $RADI – and the valuation has soared 5,000% in just 4 years*.

This is what getting "in" early feels like. Missed Nvidia? Missed Shopify? This is your second shot. Shares are now available at $0.85 – but that changes TONIGHT.

👉 Secure Your Shares Before the Price Change Tonight

- RAD INTEL

_{*This valuation has been set by RAD Intel.}

_{DISCLOSURE: This is a paid advertisement for RAD Intel's made pursuant to Reg A+ offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radintel.ai.}

UiPath did not fall because the quarter was bad.

It fell because the quarter was good in a market that now demands more than “good” from anything tied to AI.

That distinction matters.

The software group is still trying to prove that AI will expand its revenue opportunity rather than compress it. Barron’s noted that UiPath’s shares had already fallen sharply over the past three months before earnings, and that the post-earnings selloff reflected concern that the company’s growth is slowing into a market that is rewarding acceleration, not deceleration.

That is the backdrop active traders need to understand. In late 2025 and early 2026, the market increasingly split software into two buckets. The first bucket contains infrastructure-linked AI winners, where demand is visibly tied to GPUs, cloud capacity, and capital spending. The second bucket contains application and workflow software names, where the market still wants proof that AI features translate into durable revenue growth and not just product demos. UiPath is in that second bucket. That is why a revenue beat was not enough.

UiPath’s own numbers show a business that is healthier operationally than the stock reaction suggests. Revenue rose 14% in the fourth quarter, faster than the 5% growth posted in Q4 FY2025. ARR climbed to $1.853 billion, up 11%, and full-year non-GAAP operating income improved to $370 million from $241 million the year before. But the stock is not trading on what just happened. It is trading on what management said comes next.

That next-step problem is simple: full-year FY2027 revenue guidance of $1.754 billion to $1.759 billion implies lower growth than the market wanted from a company repositioning itself around agentic automation. Barron’s highlighted that the high end of guidance implies only about 9% growth, down from 13% in FY2026, and that is exactly the kind of deceleration that can weigh on a mid-cap software name even when margins improve.

The cleanest way to read UiPath’s quarter is to separate the earnings report into three layers.

The first layer is the reported quarter.

By that standard, UiPath delivered a solid result. Q4 revenue was $481 million, up 14% year over year. ARR finished at $1.853 billion, up 11%. Net new ARR was $70 million. Dollar-based net retention rate was 107%. GAAP gross margin came in at 85%, non-GAAP gross margin at 86%, and GAAP operating income reached $80 million. Non-GAAP operating income was $150 million. Operating cash flow and adjusted free cash flow were both $182 million.

The second layer is the full-year picture.

That also looks constructive. UiPath generated $1.611 billion of revenue in FY2026, up 13% from FY2025 revenue of $1.430 billion. GAAP operating income improved to $57 million from a GAAP operating loss of $163 million in FY2025. Non-GAAP operating income rose to $370 million from $241 million. Operating cash flow increased to $371 million from $321 million, and adjusted free cash flow improved to $372 million from $328 million. In other words, this was a year of real operating leverage, not accounting noise.

The third layer is the guidance.

That is where the stock broke.

For Q1 FY2027, UiPath guided to revenue of $395 million to $400 million, ARR of $1.894 billion to $1.899 billion, and non-GAAP operating income of about $80 million. For the full year, management guided to revenue of $1.754 billion to $1.759 billion, ARR of $2.051 billion to $2.056 billion, and non-GAAP operating income of about $415 million. That means the company expects to remain profitable and keep expanding ARR, but not at a pace that changes the market’s skepticism about software growth.

And that skepticism has some basis in the numbers.

The revenue growth cadence tells the story. Q4 FY2025 revenue was $424 million, up 5% year over year. Q3 FY2026 revenue was $411 million, up 16%. Q4 FY2026 revenue was $481 million, up 14%. So there has been improvement, but not the kind of explosive reacceleration that gets the market to pay a premium multiple. ARR growth has also slowed from 14% in Q4 FY2025 to 11% in both Q3 and Q4 FY2026. Dollar-based net retention likewise eased from 110% in Q4 FY2025 to 107% in Q3 and Q4 FY2026.

That leaves UiPath in an awkward valuation zone.

At a market capitalization of about $8.42 billion and share price of $11.37 on March 12, the stock trades at roughly 4.8 times the midpoint of FY2027 revenue guidance. That is not expensive relative to higher-growth software names, but it also is not obviously distressed if growth is slipping toward the high single digits. The market appears to be saying the stock is not broken because margins are bad. It is under pressure because the revenue story still lacks urgency.

Management’s strategic message is that UiPath is no longer just an RPA company.

It wants to be understood as the execution layer for the “agentic” enterprise.

Daniel Dines said customers increasingly need a platform that can execute complex processes with reliability, governance, and scale, and framed UiPath as combining deterministic automation, agentic AI, and orchestration in one governed platform. Recent business updates support that framing: the company launched new healthcare AI solutions, announced the WorkFusion acquisition for financial crime compliance, joined Veeva’s AI partner program, and integrated with Talkdesk for regulated customer experience workflows.

Strategically, that makes sense.

The pitch is that generic AI models can generate content or suggestions, but businesses still need software that can execute tasks, touch systems of record, comply with policies, and keep humans in the loop. UiPath wants to own that layer. The problem for the stock is that this is still more of a positioning argument than a visible growth breakout. Investors want proof that “agentic automation” can lift growth rates and net retention meaningfully. So far, the company has shown stable execution, not a sharp demand inflection.

UiPath’s earnings matter beyond UiPath because they say something about enterprise software in 2026.

The first implication is that profitability alone is not enough.

UiPath just achieved its first full year of GAAP profitability and still got sold. That means the market is currently paying more attention to revenue durability than margin cleanup for software names tied to AI narratives.

The second implication is that competition remains part of the story.

Barron’s specifically cited competitive pressure from larger firms such as Microsoft and ServiceNow in explaining the cautious post-earnings tone from analysts. That matters because UiPath is operating in a market where workflow, automation, orchestration, and AI assistants are increasingly overlapping categories. When larger platforms encroach, investors start asking whether specialized vendors will gain from AI or get absorbed by it.

The third implication is that software investors are demanding cleaner evidence of AI monetization.

UiPath’s guidance was not terrible. In fact, one market summary noted that the full-year revenue outlook was above consensus near $1.74 billion. But the stock still fell because the market was looking for a narrative shift, not a slight beat to models. In this tape, “above consensus” is not enough if the implied growth rate still looks ordinary.

For active traders, the setup is more useful if you stop thinking about the quarter as a binary beat-or-miss and start thinking about it as a failed re-rating attempt.

PATH closed March 12 at $11.37, down 8.24% on the day, after trading as high as $11.97 and as low as $10.73, with volume above 90 million shares. That kind of volume tells you institutions and fast money were both involved. This was not a sleepy software selloff.

The first technical level that matters is the intraday low near $10.73. If the stock breaks that area decisively on follow-through volume, the market is likely signaling that investors want to de-rate the name into the lower end of its recent valuation range. The next question would become whether the market starts anchoring around the 52-week low region referenced in pre-earnings coverage near $9.38.

The second level is the post-earnings gap zone between roughly $11.90 and $12.40. That area matters because it approximates where the stock traded before the full guidance read-through hit. If PATH cannot reclaim that band, then the market is treating the quarter as confirmation of slower-growth status. If it does reclaim it, then traders can argue the first-day move was an overreaction to guidance optics.

From a VWAP and momentum standpoint, the key issue is whether PATH can stop behaving like a “sell the rip” name. On the first post-earnings session, the stock failed to hold higher prices and closed closer to the lower half of the day’s range than the upper half. That is not what strong earnings continuation usually looks like. It suggests sellers were using liquidity to exit rather than new buyers using weakness to build positions aggressively.

The bull case is that the market has already punished the stock enough and starts to focus on quality rather than just growth optics.

For that to happen, traders would need to see PATH stabilize above the low-$11 area, reclaim part of the post-earnings gap, and attract analyst commentary that emphasizes cash generation, buybacks, and the attractiveness of the valuation at roughly 5x forward revenue. The supporting facts are there: $372 million of adjusted free cash flow in FY2026, $1.69 billion of cash and marketable securities, a new $500 million buyback, and the first full year of GAAP profitability.

The base case is a messy digestion phase.

That would mean the stock chops around while investors debate whether UiPath deserves to trade like a quality value software name or a structurally challenged automation vendor. This is the most probable near-term path because the quarter gave both bulls and bears ammunition. Bulls have the margin profile and buyback. Bears have the slowing growth rate and softer enthusiasm around the outlook.

The bear case is that the market decides the guidance is the real story and keeps compressing the multiple.

That would likely involve more target cuts, continued concern about AI cannibalization or competition, and failure to hold the $10.73 low. Barron’s already reported that UBS cut its target to $13 and that Oppenheimer stayed neutral. If those kinds of revisions spread and the stock cannot absorb supply, PATH could keep trading like a name stuck between “too slow for growth” and “not cheap enough for deep value.”

For traders, the correct question is not “was this quarter good?”

It was.

The correct question is whether the market has already priced in the disappointment from the FY2027 growth profile.

That means watching three things.

First, watch whether PATH can hold above the first post-earnings low near $10.73. A hold there suggests the market is finding a clearing price. A break there suggests further de-rating.

Second, watch analyst revisions over the next several sessions. Barron’s already highlighted a UBS target cut and a neutral Oppenheimer stance. If the revision cycle broadens but the stock stops going down, that can be constructive. If targets come down and the stock keeps making lower lows, the market is telling you the fundamental reset is still ongoing.

Third, watch the relative performance of software peers. If the entire group remains under pressure while AI infrastructure keeps attracting capital, UiPath will have a hard time staging a durable rebound. If software starts to stabilize and the market begins rewarding profitable names with buybacks and solid cash flow, PATH has a better chance of re-rating from depressed levels.

UiPath’s earnings were not a disaster.

They were something more frustrating for bulls: a respectable quarter attached to an outlook that was not strong enough to change the narrative.

The company delivered $481 million in Q4 revenue, $1.853 billion in ARR, 85% GAAP gross margin, $150 million of non-GAAP operating income, and its first full year of GAAP profitability. It ended the year with $1.69 billion in cash and approved another $500 million in buybacks. Those are the numbers of a better-run company than PATH was a year ago.

But the stock is trading on deceleration. FY2027 revenue guidance of $1.754 billion to $1.759 billion implies only about 9% growth at the high end, and that was not enough for a market that wants clear AI-led acceleration from software names. That is why PATH fell even after a beat.

For active traders, this is now a levels-and-expectations story. If the stock can hold support and absorb analyst downgrades or target cuts, the selloff may eventually look exhausted. If it cannot, then the market is still repricing UiPath from an AI hope story into a slower-growth software utility.

_{Editorial Disclaimer}

_{This commentary is for informational and educational purposes only and does not constitute investment advice. All market strategies involve risk, and past performance is not indicative of future results. Readers should conduct their own analysis or consult a licensed financial professional before making investment decisions.}